DOCSLIB.ORG

TEXTBOOK of RADIOPHARMACY Theory and Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TEXTBOOK of RADIOPHARMACY Theory and Practice TEXTBOOK OF RADIOPHARMACY Theory and Practice SECOND EDITION Edited by CHARLES B. SAMPSON Addenbrooke's Hospital Cambridge, UK Gordon and Breach Publishers Australia • Austria • China • France • Germany • India • Japan • Luxembourg • B Malaysia • Netherlands • Russia • Singapore • Switzerland • Thailand • United Kingdom • United States CONTENTS ireword to the Second Edition xii eface to the First Edition xiii eface to the Second Edition xv it of Contributors xvi SECTION I Theoretical aspects 1. BASIC PRINCIPLES OF RADIONUCLIDE PHYSICS 1 M.D. Short 1.1 Introduction 1 1.2 Basic concepts of ionising radiation 1 1.3 Structure of the atom and nucleus 2 1.4 Radionuclides and modes of decay 4 1.5 Radionuclide decay schemes 6 1.6 Radioactive decay law 8 1.7 Units of radioactivity 10 1.8 Interaction of radiation with matter 10 1.9 Radionuclide production 14 1.10 Summary of physical data for selected radionuclides 16 1.11 Further reading 17 2. RADIONUCLIDE GENERATORS 19 A.T. Elliott 2.1 Introduction 19 2.2 Theory of a generator system 19 2.3 Radionuclide separation techniques 20 2.4 Generator systems 21 2.5 Routine quality control 26 2.6 Problems 27 2.7 Conclusion 28 References 28 3. PHYSICO-CHEMICAL CONCEPTS IN THE PREPARATION OF TECHNETIUM RADIOPHARMACEUTICALS 29 D.P. Nowotnik 3.1 Introduction 29 3.2 Chemistry of technetium 29 3.3 Technetium cold kit components 32 3.4 Technetium complexes in nuclear medicine 33 3.5 The preparation of technetium radiopharmaceuticals 42 3.6 The importance of specific activity and radiolysis 43 3.7 Conclusions 43 References 44 v Contents SECTION II Practical radiopharmaceutics 4. DESIGN OF HOSPITAL RADIOPHARMACY LABORATORIES CR. Lazarus 4.1 Introduction 4.2 Aims of radiopharmacy design 4.3 Factors to be considered in radiopharmacy design 4.4 Recommendations 4.5 Conclusions Further reading 5. TECHNIQUES FOR DISPENSING OF RADIOPHARMACEUTICALS CR. Lazarus 5.1 Introduction 5.2 General working procedures 5.3 'Open' and 'Closed' procedures 5.4 Dispensing procedures 5.5 Use and maintenance of contained workstations 5.6 Conclusions Further reading References 6. RADIOLABELLING OF BLOOD CELLS - THEORY HJ. Danpure and S. Osman 6.1 Introduction 6.2 Properties of an ideal cell labelling agent 6.3 Chelating agents used in cell labelling 6.4 Choice of radionuclide 6.5 Parameters required for successful cell labelling 6.6 Health and safety aspects in working with blood cells References 7. RADIOLABELLING OF BLOOD CELLS - METHODOLOGY HJ. Danpure and S. Osman 7.1 Introduction 7.2 Radiolabelling erythrocytes 7.3 Radiolabelling leucocytes 7.4 Radiolabelling platelets 7.5 Conclusions Acknowledgements References 8. RADIOLABELLED ANTIBODIES AS RADIOPHARMACEUTICALS S.J. Mather 8.1 Introduction 8.2 Tumour antigens 8.3 Antibody production 8.4 Characterisation of antibodies in Contents 8.5 Radiolabelled antibodies 89 8.6 Antibody analysis and quality control 92 8.7 Animal models for radiolabelled antibodies 95 8.8 Pharmacokinetic aspects of radiolabelled antibodies 96 8.9 Clinical uses of radiolabelled antibodies 98 8.10 Conclusion 98 References 100 Recommended further reading 101 9. QUALITY CONTROL OF RADIOPHARMACEUTICALS 103 A.E. Theobald 9-1 Introduction 103 92 Quality control parameters 104 9-3 Radiochemical purity determinations 109 9.4 Panicle sizing 122 95 Particulate contamination 123 9.6 Control of pH 123 97 Biological distribution tests 123 9.8 Summary and conclusions 123 References 123 10. FACTORS WHICH AFFECT THE INTEGRITY OF RADIOPHARMACEUTICALS 145 C. Hojelse, K. Kristensen and C.B. Sampson 10.1 Introduction 145 10.2 General defects 145 10.3 Registration of defects 150 10.4 Conclusion 150 References 151 11. DOCUMENTATION, LABELLING, PACKAGING AND TRANSPORTATION 153 A.M. Millar and K.E. Goldstone 11.1 Introduction 153 11.2 Documentation 153 11.3 Labelling 156 11.4 Packaging and transport 157 11.5 Summary of records to be kept in a radiopharmacy 159 References 159 12. MICROBIAL AND RADIATION MONITORING IN THE RADIOPHARMACY l6l S.R. Hesslewood 12.1 Introduction l6l 12.2 Sources of particulate contamination in radiopharmacies 161 12.3 Procedures for reducing microbial and particulate contamination 162 12.4 Consequences of particulate contamination of radiopharmaceuticals 163 12.5 Detection of microbial and particulate contamination in the radiopharmacy 164 12.6 Radioactive contamination of radiopharmacies 165 12.7 Monitoring of radioactivity levels in radiopharmacies 166 References 167 vii Contents 13. WASTE MANAGEMENT IN THE RADIOPHARMACY 169 A.T. Elliott 13-1 Introduction 169 13-2 Radioactive waste management löl 13-3 Radioactive waste store 169 134 Disposal of radioactive waste 169y 13.5 Records 17 References ! 14. OPERATOR SAFETY IN THE HANDLING OF RADIOPHARMACEUTICALS 17: S.R. Hesslewood 14.1 Introduction 173 14.2 Regulations and codes of practice 173 14.3 Handling of radioactive materials in the radiopharmacy 174 14.4 Personnel monitoring 176 14.5 Accidents in the radiopharmacy 178 14.6 Conclusions 180 15. REGULATORY REQUIREMENTS FOR THE DISPENSING AND SUPPLY OF RADIOPHARMACEUTICALS J.R. Gill and J.L. Turner 15.1 Introduction 181 15.2 The Medicines Act 1968 181 15.3 The Health and Safety at Work etc. Act 1974 185 15.4 The European Community 190 15.5 The preparation and supply of radiopharmaceuticals in the National Health Service 191 15.6 Summary 192 References 192 Further reading 192 16. OFFICIAL AND NON-OFFICIAL RADIOPHARMACEUTICALS AND THEIR PROPERTIES 193 P.J. Maltby 16.1 Introduction 193 16.2 Official radiopharmaceuticals 193 16.3 Non-official radiopharmaceuticals 198 16.4 Conclusion 200 Further reading 200 SECTION III Localisation and disposition of radiopharmaceuticals 17. MECHANISMS OF LOCALISATION OF RADIOPHARMACEUTICALS 201 M. Frier 17.1 Introduction 201 17.2 Modes of localisation 201 17.3 Summary and conclusion 206 References 206 Further reading 207 Vltl Contents 18. PHARMACOLOGY, PHARMACOKINETICS AND METABOLISM OF RADIOPHARMACEUTICALS 209 M. Frier 18.1 Introduction 209 18.2 Myocardial agents 209 18.3 Skeletal agents 210 18.4 Renal agents 210 18.5 Particulate agents 211 18.6 Brain blood flow agents 212 18.7 Hepatobiliary agents 212 18.8 Conclusion 213 References 213 19. EFFECT OF PATIENT MEDICATION AND OTHER FACTORS ON THE BIODISTRIBUTION OF RADIOPHARMACEUTICALS 215 C.B. Sampson and P.H. Cox 19-1 Introduction 215 19.2 Classification of drug/radiopharmaceutical interactions 215 19-3 Effects of radiation therapy and other extraneous factors 224 19.4 Diet 226 19.5 Registration of instances of abnormal biodistribution 226 References 226 20. USE OF DRUGS TO ENHANCE NUCLEAR MEDICINE STUDIES 229 S.C.E. Leung and S.R. Hesslewood 20.1 Introduction 229 20.2 Cardiac studies 229 20.3 Renal studies 230 20.4 Hepatobiliary studies 231 20.5 Gastrointestinal studies 233 20.6 Adrenal studies 234 20.7 Brain studies 235 20.8 Thyroid studies 235 20.9 Conclusion 236 References 236 ECTION IV Clinical radiopharmacy 21. DIAGNOSTIC APPLICATIONS OF RADIOPHARMACEUTICALS 243 L. Smith 21.1 Introduction 243 21.2 Imaging studies 243 21.3 Non-imaging studies 264 21.4 Conclusions 266 References 267 Further reading 267 ix Contents 22. THERAPEUTIC APPLICATIONS OF RADIOPHARMACEUTICALS 2691 D.T. Murray and T.E. Hilditch 22.1 Introduction 269 j 22.2 Factors determining the effectiveness of radionuclide therapy 26S 22.3 Clinical applications 272 References 281 23. ADVERSE REACTIONS AND UNTOWARD EVENTS ASSOCIATED WITH THE USE OF RADIOPHARMACEUTICALS D.H. Keeling 23-1 Introduction 23-2 Definitions 23-3 Classification 23-4 Radiation effects 23.5 Pharmacology of hypersensitive reactions 23-6 Pyrogens 23.7 Sterility 23.8 Reporting schemes 23-9 Interpretation of reports 23.10 Results of reporting schemes 23-11 Incidence References 24. DOSIMETRIC ASPECTS M. Pillay 24.1 Introduction 24.2 Biological effects of radiation 24.3 Definitions and units 24.4 Parameters required for internal dose calculations Further reading 25. NEW RADIOPHARMACEUTICALS P.H. Cox and S.J. Mather 251 Introduction 25.2 Positron emitting radiopharmaceuticals 25.3 Single photon emitting radiopharmaceuticals 25.4 Generator systems for P.E.T. 25.5 New carrier molecules References 26. USE OF RADIOPHARMACEUTICALS IN THE EVALUATION OF DRUG FORMULATIONS J.G. Hardy 26.1 Introduction 26.2 Oral dosage forms 26.3 Rectal formulations 26.4 Ophthalmic formulations 26.5 Formulations for inhalation 26.6 Nasal formulations 26.7 Conclusion References Contents ACTION V Paediatric radiopharmacy 27. PAEDIATRIC RADIOPHARMACY 327 K. Evans 27.1 Introduction 327 27.2 Administered doses 328 27.3 Preparation of doses and documentation 330 27.4 Immobilisation of children 331 27.5 Sedation 332 27.6 Injection techniques 332 27.7 Organ depth correction 332 27.8 Absorbed radiation dose 333 References 334 Further reading 337 tpendix A: Summary of decay parameters of some commonly used radionucliotides 339 »pendix B: Mean weight (kilogrammes) of babies and children 346 dex 347 xi .
Load more

Recommended publications
  • Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1
    Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1 Published by Health Physics Society 1313 Dolley Madison Blvd. Suite 402 McLean, VA 22101 Disclaimer Statements and opinions expressed in publications of the Health Physics Society or in presentations given during its regular meetings are those of the author(s) and do not necessarily reflect the official position of the Health Physics Society, the editors, or the organizations with which the authors are affiliated. The editor(s), publisher, and Society disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any product or service mentioned. Official positions of the Society are established only by its Board of Directors. Copyright © 2017 by the Health Physics Society All rights reserved. No part of this publication may be reproduced or distributed in any form, in an electronic retrieval system or otherwise, without prior written permission of the publisher. Printed in the United States of America SP001-1, revised 2017 Radiation and Risk: Expert Perspectives Table of Contents Foreword……………………………………………………………………………………………………………... 2 A Primer on Ionizing Radiation……………………………………………………………………………... 6 Growing Importance of Nuclear Technology in Medicine……………………………………….. 16 Distinguishing Risk: Use and Overuse of Radiation in Medicine………………………………. 22 Nuclear Energy: The Environmental Context…………………………………………………………. 27 Nuclear Power in the United States: Safety, Emergency Response Planning, and Continuous Learning…………………………………………………………………………………………….. 33 Radiation Risk: Used Nuclear Fuel and Radioactive Waste Disposal………………………... 42 Radiation Risk: Communicating to the Public………………………………………………………… 45 After Fukushima: Implications for Public Policy and Communications……………………. 51 Appendix 1: Radiation Units and Measurements……………………………………………………. 57 Appendix 2: Half-Life of Some Radionuclides…………………………………………………………. 58 Bernard L.
    [Show full text]
  • Nuclear Fusion Enhances Cancer Cell Killing Efficacy in a Protontherapy Model
    Nuclear fusion enhances cancer cell killing efficacy in a protontherapy model GAP Cirrone*, L Manti, D Margarone, L Giuffrida, A. Picciotto, G. Cuttone, G. Korn, V. Marchese, G. Milluzzo, G. Petringa, F. Perozziello, F. Romano, V. Scuderi * Corresponding author Abstract Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, economic and radiobiological issues hamper 12C-ion clinical amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + 11Bà3a reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-triggered alpha-particles. We recorded significantly increased cellular lethality and chromosome aberration complexity. A strategy combining protontherapy’s ballistic precision with the higher RBE promised by BNCT and 12C-ion therapy is thus demonstrated. 1 The urgent need for radical radiotherapy research to achieve improved tumour control in the context of reducing the risk of normal tissue toxicity and late-occurring sequelae, has driven the fast- growing development of cancer treatment by accelerated beams of charged particles (hadrontherapy) in recent decades (1). This appears to be particularly true for protontherapy, which has emerged as the most-rapidly expanding hadrontherapy approach, totalling over 100,000 patients treated thus far worldwide (2).
    [Show full text]
  • Radiation and Your Patient: a Guide for Medical Practitioners
    RADIATION AND YOUR PATIENT: A GUIDE FOR MEDICAL PRACTITIONERS A web module produced by Committee 3 of the International Commission on Radiological Protection (ICRP) What is the purpose of this document ? In the past 100 years, diagnostic radiology, nuclear medicine and radiation therapy have evolved from the original crude practices to advanced techniques that form an essential tool for all branches and specialties of medicine. The inherent properties of ionising radiation provide many benefits but also may cause potential harm. In the practice of medicine, there must be a judgement made concerning the benefit/risk ratio. This requires not only knowledge of medicine but also of the radiation risks. This document is designed to provide basic information on radiation mechanisms, the dose from various medical radiation sources, the magnitude and type of risk, as well as answers to commonly asked questions (e.g radiation and pregnancy). As a matter of ease in reading, the text is in a question and answer format. Interventional cardiologists, radiologists, orthopaedic and vascular surgeons and others, who actually operate medical x-ray equipment or use radiation sources, should possess more information on proper technique and dose management than is contained here. However, this text may provide a useful starting point. The most common ionising radiations used in medicine are X, gamma, beta rays and electrons. Ionising radiation is only one part of the electromagnetic spectrum. There are numerous other radiations (e.g. visible light, infrared waves, high frequency and radiofrequency electromagnetic waves) that do not posses the ability to ionize atoms of the absorbing matter.
    [Show full text]
  • Literature Survey on Decorporation of Radionuclides from the Human Body
    Literature Survey on Decorporation of Radionuclides from the Human Body E.A. Waller, R.Z. Stodilka, K. Leach and L. Prud’homme-Lalonde Defence R&D Canada - Ottawa TECHNICAL MEMORANDUM DRDC Ottawa TM 2002-042 April 2002 Literature Survey on Decorporation of Radionuclides from the Human Body E.A. Waller SAIC Canada, Inc R.Z. Stodilka, K. Leach and L. Prud’homme-Lalonde Space Systems and Technology Defence R&D Canada - Ottawa Technical Memorandum DRDC Ottawa TM 2002-042 April 2002 © Her Majesty the Queen as represented by the Minister of National Defence, 2002 © Sa majesté la reine, représentée par le ministre de la Défense nationale, 2002 Abstract The broad use of radionuclides by many industries has greatly increased the probability of events that could lead to internalized contamination. Examples include accidents and/or intentional damage to nuclear power plants or radiation therapy units in hospitals, the use of radiological dispersal weapons, and lost or stolen radionuclide sources. Developing effective countermeasures requires knowledge of the physical and chemical composition of the radionuclides, their metabolic activities within the body, and methods to expedite their elimination from the body. This report presents a summary of information pertaining to intake and decorporation of radionuclides from humans. This information would be the first step in establishing a field protocol to guide physicians in military missions. Developing such a guide requires an understanding of the dangers associated with internal radioisotope contamination, decision levels for administering therapy (risk vs. benefit) and protocols for administering therapy. As presented, this study could be used to decide what decorporation pharmaceuticals should be maintained in quantity by the military, and how to best train officers with medical responsibilities.
    [Show full text]
  • And Stereotactic Body Radiation Therapy (SBRT)
    Geisinger Health Plan Policies and Procedure Manual Policy: MP084 Section: Medical Benefit Policy Subject: Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy I. Policy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) II. Purpose/Objective: To provide a policy of coverage regarding Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) III. Responsibility: A. Medical Directors B. Medical Management IV. Required Definitions 1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy. 2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy. 3. Devised – the date the policy was implemented. 4. Revised – the date of every revision to the policy, including typographical and grammatical changes. 5. Reviewed – the date documenting the annual review if the policy has no revisions necessary. V. Additional Definitions Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are: a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury; b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury; c. in accordance with current standards of good medical treatment practiced by the general medical community. d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.
    [Show full text]
  • New Discoveries in Radiation Science
    cancers Editorial New Discoveries in Radiation Science Géza Sáfrány 1,*, Katalin Lumniczky 1 and Lorenzo Manti 2 1 Department Radiobiology and Radiohygiene, National Public Health Center, 1221 Budapest, Hungary; [email protected] 2 Department of Physics, University of Naples Federico II, 80126 Naples, Italy; [email protected] * Correspondence: [email protected]; Tel.: +36-309199218 This series of 16 articles (8 original articles and 8 reviews) was written by internation- ally recognized scientists attending the 44th Congress of the European Radiation Research Society (Pécs, Hungary). Ionizing radiation is an interesting agent because it is used to cure cancers and can also induce cancer. The effects of ionizing radiation at the organism level depend on the response of the cells. When radiation hits a cell, it might damage any cellular organelles and macromolecules. Unrepairable damage leads to cell death, while misrepaired alterations leave mutations in surviving cells. If the repair is errorless, normal cells will survive. However, in a small percentage of the seemingly healthy cells the number of spontaneous mutations will increase, which is a sign of radiation-induced genomic instability. Radiation-induced cell death is behind the development of acute radiation syndromes and the killing of tumorous and normal cells during radiation therapy. Radiation-induced mutations in surviving cells might lead to the induction of tumors. According to the central paradigm of radiation biology, the genetic material, that is the DNA, is the main cellular target of ionizing radiation. Many different types of damage are induced by radiation in the DNA, but the most deleterious effects arise from double strand breaks (DSBs).
    [Show full text]
  • Radiation Therapy
    Radiation Therapy What is radiation therapy? Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A doctor who uses radiation therapy to treat cancer is called a radiation oncologist. The goal of radiation therapy is to destroy the cancer cells without harming nearby healthy tissue. It may be used along with other cancer treatments or as the main treatment. Sometimes radiation therapy is used to relieve symptoms, called palliative radiation therapy. More than half of all people with cancer receive some type of radiation therapy. What are the different types of radiation therapy? The most common type is called external-beam radiation therapy, which is radiation given from a machine located outside the body. Types of external-beam radiation therapy include proton therapy, 3-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiation therapy. Sometimes radiation therapy involves bringing a radioactive source close to a tumor. This is called internal radiation therapy or brachytherapy. The type you receive depends on many factors. Learn more about radiation treatment at www.cancer.net/radiationtherapy. What should I expect during radiation therapy? Before treatment begins, you will meet with the radiation oncologist to review your medical history and discuss the potential risks and benefits. If you choose to receive radiation therapy, you may undergo tests to plan the treatment and evaluate the results. Before radiation therapy begins, it must be planned carefully. This planning stage is often called a “simulation.” During this visit, the medical team will figure out the best position for you to be in during treatment.
    [Show full text]
  • A Framework for Quality Radiation Oncology Care
    Safety is No Accident A FRAMEWORK FOR QUALITY RADIATION ONCOLOGY CARE DEVELOPED AND SPONSORED BY Safety is No Accident A FRAMEWORK FOR QUALITY RADIATION ONCOLOGY CARE DEVELOPED AND SPONSORED BY: American Society for Radiation Oncology (ASTRO) ENDORSED BY: American Association of Medical Dosimetrists (AAMD) American Association of Physicists in Medicine (AAPM) American Board of Radiology (ABR) American Brachytherapy Society (ABS) American College of Radiology (ACR) American Radium Society (ARS) American Society of Radiologic Technologists (ASRT) Society of Chairmen of Academic Radiation Oncology Programs (SCAROP) Society for Radiation Oncology Administrators (SROA) T A R G E T I N G CAN CER CAR E The content in this publication is current as of the publication date. The information and opinions provided in the book are based on current and accessible evidence and consensus in the radiation oncology community. However, no such guide can be all-inclusive, and, especially given the evolving environment in which we practice, the recommendations and information provided in the book are subject to change and are intended to be updated over time. This book is made available to ASTRO and endorsing organization members and to the public for educational and informational purposes only. Any commercial use of this book or any content in this book without the prior written consent of ASTRO is strictly prohibited. The information in the book presents scientific, health and safety information and may, to some extent, reflect ASTRO’s and the endorsing organizations’ understanding of the consensus scientific or medical opinion. ASTRO and the endorsing organizations regard any consideration of the information in the book to be voluntary.
    [Show full text]
  • Internal and External Exposure Exposure Routes 2.1
    Exposure Routes Internal and External Exposure Exposure Routes 2.1 External exposure Internal exposure Body surface From outer space contamination and the sun Inhalation Suspended matters Food and drink consumption From a radiation Lungs generator Radio‐ pharmaceuticals Wound Buildings Ground Radiation coming from outside the body Radiation emitted within the body Radioactive The body is equally exposed to radiation in both cases. materials "Radiation exposure" refers to the situation where the body is in the presence of radiation. There are two types of radiation exposure, "internal exposure" and "external exposure." External exposure means to receive radiation that comes from radioactive materials existing on the ground, suspended in the air, or attached to clothes or the surface of the body (p.25 of Vol. 1, "External Exposure and Skin"). Conversely, internal exposure is caused (i) when a person has a meal and takes in radioactive materials in the food or drink (ingestion); (ii) when a person breathes in radioactive materials in the air (inhalation); (iii) when radioactive materials are absorbed through the skin (percutaneous absorption); (iv) when radioactive materials enter the body from a wound (wound contamination); and (v) when radiopharmaceuticals containing radioactive materials are administered for the purpose of medical treatment. Once radioactive materials enter the body, the body will continue to be exposed to radiation until the radioactive materials are excreted in the urine or feces (biological half-life) or as the radioactivity weakens over time (p.26 of Vol. 1, "Internal Exposure"). The difference between internal exposure and external exposure lies in whether the source that emits radiation is inside or outside the body.
    [Show full text]
  • Chapter 5 TREATMENT MACHINES for EXTERNAL BEAM
    Chapter 5 TREATMENT MACHINES FOR EXTERNAL BEAM RADIOTHERAPY E.B. PODGORSAK Department of Medical Physics, McGill University Health Centre, Montreal, Quebec, Canada 5.1. INTRODUCTION Since the inception of radiotherapy soon after the discovery of X rays by Roentgen in 1895, the technology of X ray production has first been aimed towards ever higher photon and electron beam energies and intensities, and more recently towards computerization and intensity modulated beam delivery. During the first 50 years of radiotherapy the technological progress was relatively slow and mainly based on X ray tubes, van de Graaff generators and betatrons. The invention of the 60Co teletherapy unit by H.E. Johns in Canada in the early 1950s provided a tremendous boost in the quest for higher photon energies and placed the cobalt unit at the forefront of radiotherapy for a number of years. The concurrently developed medical linacs, however, soon eclipsed cobalt units, moved through five increasingly sophisticated generations and became the most widely used radiation source in modern radiotherapy. With its compact and efficient design, the linac offers excellent versatility for use in radiotherapy through isocentric mounting and provides either electron or megavoltage X ray therapy with a wide range of energies. In addition to linacs, electron and X ray radiotherapy is also carried out with other types of accelerator, such as betatrons and microtrons. More exotic particles, such as protons, neutrons, heavy ions and negative p mesons, all produced by special accelerators, are also sometimes used for radiotherapy; however, most contemporary radiotherapy is carried out with linacs or teletherapy cobalt units.
    [Show full text]
  • This File Was Downloaded From
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Queensland University of Technology ePrints Archive This is the author’s version of a work that was submitted/accepted for pub- lication in the following source: Poole, Christopher, Trapp, Jamie, Kenny, John, Kairn, Tanya, Williams, Kerry, Taylor, Michael, Franich, Rick, & Langton, Christian M. (2011) A hybrid radiation detector for simultaneous spatial and temporal dosimetry. Australasian Physical and Engineering Sciences in Medicine, 34(3), pp. 327-332. This file was downloaded from: http://eprints.qut.edu.au/42062/ c Copyright 2011 Australasian College of Physical Scientists and Engineers in Medicine Notice: Changes introduced as a result of publishing processes such as copy-editing and formatting may not be reflected in this document. For a definitive version of this work, please refer to the published source: http://dx.doi.org/10.1007/s13246-011-0081-5 A hybrid radiation detector for simultaneous spatial and temporal dosimetry C. Poole1 , J.V. Trapp1*, J. Kenny2 ,T. Kairn2 , K. Williams3, M. Taylor3, R. Franich3, C.M. Langton1 1. Physics, Faculty of Science and Technology, Queensland University of Technology, GPO Box 2434, Brisbane Qld 4001, Australia 2. Premion, The Wesley Medical Centre, Suite 1 40 Chasely Street, Auchenflower Queensland 4066, Australia 3. School of Applied Sciences, RMIT University, GPO Box 2476, Melbourne 3001, Australia *Corresponding Author: Email: [email protected], Phone +61 7 31381386, Fax +61 7 1389079 Keywords: Radiotherapy, Dosimetry, Gel Dosimetry, Radiation Measurement, 4D dosimetry 1 Abstract In this feasibility study an organic plastic scintillator is calibrated against ionisation chamber measurements and then embedded in a polymer gel dosimeter to obtain a quasi-4D experimental measurement of a radiation field.
    [Show full text]
  • Computation of Delayed Fission Product Gamma Ray Dose Rates from NCSU PULSTAR Reactor Using a Monte Carlo Number Albedo Approach
    Attachment 5 Computation of Delayed Fission Product Gamma Ray Dose Rates from NCSU PULSTAR Reactor Using a Monte Carlo Number Albedo Approach B.E. Hey ABSTRACT Hey, Brit Elkington. Computation of Delayed Fisson-Product Gamma-Ray Dose Rates From NCSU PULSTAR Reactor Using a Monte Carlo Number Albedo Approach.(Under the direction of Dr. J. M. Doster.) The dose rate due to decaying fission-product gamma-rays escaping the PULSTAR reactor 10 minutes after a loss of water accident was investigated. A Monte Carlo simulation of the accident was developed using the departmental VAX-11/730 mini-computer. Dose rates were calculated at several hundred point detector locations in and around the Burlington facility so that isodose lines (lines of constant dose rate) could be established. Work preliminary to the simulation included the construction of a table of gamma-ray number albedos for use in sampling and dose estimation. It was found that many areas would be exposed to gamma radiation fields of significant intensity. The dose rate computed 20 feet directly over and in line-of-sight of the core was 230 +- 10 Rem/hr. The maximum dose rate computed on the bay floor was 175 +- 12 mRem/hr. Gamma-ray streaming through bay doors and windows resulted in maximum dose rates of 250 +- 13 mRem/hr and 175 +- 9 mRem/hr in the control room and loading dock respectively. The exposure occurring outside the reactor building was due primarily to skyshine and caused dose rates on the order of 4 +- 0.3 mRem/hr next to the building.
    [Show full text]